Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs Drug ChannelsBy Adam J.Read full story pharminent June 2, 2026 (Last updated: June 4, 2026) Drug Channels By Adam J. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancerNext: Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb Related Stories Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy pharminent June 24, 2026 Policy / Pricing US launches probe of German ‘underpayment’ for medicines pharminent June 19, 2026 Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026
